Optimer Pharmaceuticals, Inc. - Optimer Pharmaceuticals to Present at August 2010 Investor Conferences

Print page Email page Download PDF
« Previous Release | Next Release »

Optimer Pharmaceuticals to Present at August 2010 Investor Conferences

SAN DIEGO, July 28, 2010 /PRNewswire via COMTEX News Network/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the Company will present at the following investor conferences:

30th Annual Canaccord Genuity Growth Conference on Thursday, August 12, 2010 at 2:00 p.m. Eastern Time at the InterContinental Boston. A live audio webcast of this presentation will be accessible on the Company's website at www.optimerpharma.com, under the investors section. A replay of this presentation will be available at the same location for 30 days after the presentation.

2010 Southern California Investor Conference on Tuesday, August 17, 2010 at 11:00 a.m. Pacific Time at the Island Hotel-Newport Beach, California.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infectives to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection. In two Phase 3 trials completed by Optimer to study the safety and efficacy of fidaxomicin for the treatment of CDI, fidaxomicin was statistically superior to vancomycin in global cure rate (defined as cure with no recurrence within four weeks of completing therapy) as well as statistically superior in reducing recurrences of CDI by up to 50% when compared with vancomycin, the only FDA approved product for CDI. Pruvel(TM) is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Optimer has also successfully completed two Phase 3 trials with Pruvel. Additional information can be found at http://www.optimerpharma.com.


    Contacts

    Optimer Pharmaceuticals, Inc.
    Christina Donaghy, Corporate Communications Manager
    John D. Prunty, Chief Financial Officer & VP Finance
    858-909-0736

    Canale Communications, Inc.
    Jason I. Spark, Senior Vice President
    619-849-6005

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

SOURCE Optimer Pharmaceuticals, Inc.

Close window | Back to top